The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

Your daily dose of the clinical news you may have missed.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

Supported by Otsuka, new research calculated the value of daily hours spent on basic chores and complex tasks required to support a loved one with AD.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

In a study of adolescents with obesity, those in the GLP-1RA group had a 33% lower risk of experiencing suicidal ideation or attempts compared with matched controls.

Your daily dose of the clinical news you may have missed.

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Higher alcohol intake was associated with a greater risk of gout for both sexes, but the correlation was stronger in men than women, according to a recent study.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.

Your daily dose of the clinical news you may have missed.

The elinzanetant NDA is based on data, including long-term efficacy, from the OASIS phase 3 clinical trial program, according to Bayer.

After a false positive outcome on screening mammography, a short interval call back for repeat imaging was a significant deterrent to future screening.

Your daily dose of the clinical news you may have missed.

CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.

Remdesivir plus dexamethasone was associated with reduced 14- and 28-day mortality vs dexamethasone alone, according to a large study of adults hospitalized with COVID-19.

CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.

Your daily dose of the clinical news you may have missed.

Obesity is a complex disease that requires a multispecialty approach to address the physical and also the mental and emotional components of the widespread disorder.

The most common harm associated with breast cancer screening is a false positive finding; this UC Davis expert wanted to know more about how women respond.